



UroGen: Advancing Our Mission to Transform Cancer Care

Webcast | February 20, 2025

Disclaimers

This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: UroGen’s strategy, including leveraging UroGen’s leadership in addressing unmet needs in urothelial cancer and drug delivery to advance care for specialty oncology patients and deliver long-term sustainable growth, winning with its current portfolio by developing UGN-102 to establish a new standard of care, optimizing JELMYTO investment to maximize returns and making a go/no go decision on advancing UGN-301 in HG-NMIBC, expanding its uro-oncology leadership by forging strategic research collaborations to benefit RTGel, evaluating and executing on life cycle management of its current portfolio, including developing UGN-103 in HG-NMIBC, and developing ICVB-1042 in NMIBC as potentially best in class, and expanding into other specialty cancers by evaluating ICVB-1042 in other tumor types and considering next best tumor for RTGel; the belief that ICVB-1042 is a promising new cancer immunotherapy; the ongoing and planned pre-clinical and clinical studies for ICVB-1042 and UGN-301, including the design and expected timing thereof; the potential for additional indications for ICVB-1042; the belief that ICVB-1042 has several attributes that differentiate it from other oncolytic viruses; the interpretation and summary of results of ICVB-1042 pre-clinical trials; the potential advantages of ICVB-1042 over competitor treatments; UroGen being poised for long-term growth; ICVB-1042’s pre-clinical, CMC and clinical data package offering a solid foundation to explore local administration; UroGen’s plans to develop ICVB-1042 to target cancer cells while retaining potency, triggering an immune response, and minimizing systemic exposure; and the potential of UroGen’s proprietary RTGel technology to enhance the clinical effectiveness of multiple immunotherapies, including optimizing dwell time to improve treatment outcomes. Words such as “believe,” “plan,” “potential,” “will,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of trials and potential safety or other complications encountered therein; results from prior or ongoing pre-clinical and clinical trials may not be indicative of results that may be observed in the future; unforeseen delays that may impact the timing of progressing clinical trials and reporting data; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with product development and commercialization activities; the labeling and packaging for any approved product; the scope, progress and expansion of developing and commercializing UroGen’s product and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; RTGel technology may not perform as expected and UroGen may not successfully develop and receive regulatory approval of any product candidate beyond JELMYTO that incorporates its RTGel technology; UroGen’s financial condition and need for additional capital; and UroGen’s ability to attract or retain key management, members of the board of directors and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission (SEC) on November 6, 2024, and other filings that UroGen makes with the SEC from time to time (which are available at <http://www.sec.gov>), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this presentation and are based on information available to UroGen as of the date of this presentation.

Agenda

Advancing Our Mission

Liz Barrett, President & CEO, UroGen

The Potential of ICVB-1042: Understanding the Science

Mark Schoenberg, MD, Chief Medical Officer, UroGen

Q&A

Advancing Our Mission

Liz Barrett, President & CEO, UroGen

UroGen's Strategy

Leverage leadership in urothelial cancer and drug delivery to advance care for specialty oncology patients and deliver long-term sustainable growth

Establish Leadership in Specialty Oncology

Win With Current Portfolio

- Develop UGN-102 to establish a new standard of care for LG-NMIBC
- Optimize JELMYTO investment to maximize return
- Go/No Go Decision on Advancing UGN-301 in HG-NMIBC

Expand Uro-Oncology Leadership

- Forge strategic research collaborations to leverage benefits of RTGel
- Evaluate and execute life cycle management of current portfolio (e.g. developing UGN-103 for HG-NMIBC)
- Develop ICVB-1042 in NMIBC as potentially Best in Class

Expand Into Other Specialty Cancers

- Evaluate ICVB-1042 in other tumor types
- Consider next best tumor for RTGel

ICVB-1042 Acquisition Rationale



MARKET ANALYSIS

- Landscape evaluation of cancer treatments in NMIBC identified ICVB-1042 as most promising among asset acquisition opportunities.
- Initiated research collaboration and subsequent acquisition of ICVB-1042 as an “opportunistic” asset.



FAVORABLE FINANCIALS

- Upfront payment using UroGen stock with minimal dilution.
- Modest financial cash payouts and larger operating costs are back-loaded when product is de-risked.




EXPANDS ONCOLOGY LEADERSHIP

- In non-clinical studies, ICVB-1042 infects and kills a broad range of tumor cells, including bladder, head and neck, lung and breast, suggesting potential utility in a wide range of solid tumor indications.


The Potential of ICVB-1042: Understanding the Science

Mark Schoenberg, MD, Chief Medical Officer, UroGen

The Potential of ICVB-1042




ICVB-1042 Is Highly Selective



- Green fluorescent protein (GFP) expression represents *in vitro* viral replication in a lung cancer cell line and normal healthy lung cells.
- Other OV is a modified version of a third-party investigational OV.
- Caution is required for the interpretation of the above visual representations. This nonclinical information is not intended to suggest or imply comparisons in clinical activity, effectiveness or safety for the agents depicted
- Unpublished Data on file

ICVB-1042 Replicates Rapidly Leading to Improved Cancer Cell Destruction



ICVB-1042 evaluated in 120+ tumor cell lines in over a dozen indications and results demonstrated broad cancer cell destruction

- YPET expression shows viral replication in a cancer cell line. Images from 9 days and 16 hours post-infection. IOV1 and IOV2 are modified versions of third-party investigational OVs. WT, wild type.
- Caution is required for the interpretation of the above graphical representations. This information is not intended to suggest or imply comparisons in pre-clinical or clinical activity, effectiveness or safety for the agents depicted
- Unpublished Data on file

Next Steps: Development Program



IND enabling studies expected to begin in 2025



Multiple modes of administration will be tested, including RTGel®



Explore ICVB-1042 in bladder and beyond urothelial cancer

An Update on UGN-301 (zalifrelimab), an Anti-CTLA4 Antibody for Use in High-Grade Bladder Cancer



Local delivery of UGN-301, formulated in an RTGel, shown to allow sustained exposure of zalifrelimab



Completed enrollment of dose escalation for UGN-301 alone and in combination with fixed dose UGN-201 or gemcitabine



Acceptable safety profile and well tolerated across all dose levels



Responses observed in monotherapy and combination therapy arms



Ongoing patient follow-up to better understand durability of responses

Poised for Long-Term Growth

Liz Barrett, President and CEO, UroGen

Summary: Advancing our Mission



ICVB-1042 acquisition is a key milestone in our long-term growth strategy.



ICVB-1042 is an OV engineered to selectively destroy cancer cells while retaining potency and trigger a robust immune response.



The existing ICVB-1042 non-clinical, CMC and clinical data package offers a solid foundation to explore local administration.



Research collaborations will explore the potential of our innovative RTGel[®] technology to enhance the clinical effectiveness of multiple immunotherapies, including its potential to optimize dwell time to improve treatment outcomes.



Together, these efforts position UroGen at the forefront of transformative cancer treatments that have the potential to profoundly improve the lives of patients.

Q & A





THANK YOU
